File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.preteyeres.2010.01.002
- Scopus: eid_2-s2.0-77951206611
- PMID: 20100589
- WOS: WOS:000277826800003
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Novel aspects of corneal angiogenic and lymphangiogenic privilege
Title | Novel aspects of corneal angiogenic and lymphangiogenic privilege | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Authors | |||||||||||
Issue Date | 2010 | ||||||||||
Publisher | Pergamon. The Journal's web site is located at http://www.elsevier.com/locate/preteyeres | ||||||||||
Citation | Progress In Retinal And Eye Research, 2010, v. 29 n. 3, p. 208-248 How to Cite? | ||||||||||
Abstract | In this article, we provide the results of experimental studies demonstrating that corneal avascularity is an active process involving the production of anti-angiogenic factors, which counterbalance the pro-angiogenic/lymphangiogenic factors that are upregulated during wound healing. We also summarize pertinent published reports regarding corneal neovascularization (NV), corneal lymphangiogenesis and corneal angiogenic/lymphangiogenic privilege. We outline the clinical causes of corneal NV, and discuss the angiogenic proteins (VEGF and bFGF) and angiogenesis regulatory proteins. We also describe the role of matrix metalloproteinases MMP-2, -7, and MT1-MMP, anti-angiogenic factors, and lymphangiogenic regulatory proteins during corneal wound healing. Established and potential new therapies for the treatment of corneal neovascularization are also discussed. © 2010. | ||||||||||
Persistent Identifier | http://hdl.handle.net/10722/147618 | ||||||||||
ISSN | 2023 Impact Factor: 18.6 2023 SCImago Journal Rankings: 5.923 | ||||||||||
ISI Accession Number ID |
Funding Information: Supported by: EY01792 (DTA), EY14048 (JHC), EY10101 (DTA), and an unrestricted grant from Research to Prevent Blindness, New York, NY. | ||||||||||
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ellenberg, D | en_US |
dc.contributor.author | Azar, DT | en_US |
dc.contributor.author | Hallak, JA | en_US |
dc.contributor.author | Tobaigy, F | en_US |
dc.contributor.author | Han, KY | en_US |
dc.contributor.author | Jain, S | en_US |
dc.contributor.author | Zhou, Z | en_US |
dc.contributor.author | Chang, JH | en_US |
dc.date.accessioned | 2012-05-29T06:05:00Z | - |
dc.date.available | 2012-05-29T06:05:00Z | - |
dc.date.issued | 2010 | en_US |
dc.identifier.citation | Progress In Retinal And Eye Research, 2010, v. 29 n. 3, p. 208-248 | en_US |
dc.identifier.issn | 1350-9462 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/147618 | - |
dc.description.abstract | In this article, we provide the results of experimental studies demonstrating that corneal avascularity is an active process involving the production of anti-angiogenic factors, which counterbalance the pro-angiogenic/lymphangiogenic factors that are upregulated during wound healing. We also summarize pertinent published reports regarding corneal neovascularization (NV), corneal lymphangiogenesis and corneal angiogenic/lymphangiogenic privilege. We outline the clinical causes of corneal NV, and discuss the angiogenic proteins (VEGF and bFGF) and angiogenesis regulatory proteins. We also describe the role of matrix metalloproteinases MMP-2, -7, and MT1-MMP, anti-angiogenic factors, and lymphangiogenic regulatory proteins during corneal wound healing. Established and potential new therapies for the treatment of corneal neovascularization are also discussed. © 2010. | en_US |
dc.language | eng | en_US |
dc.publisher | Pergamon. The Journal's web site is located at http://www.elsevier.com/locate/preteyeres | en_US |
dc.relation.ispartof | Progress in Retinal and Eye Research | en_US |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Cornea - Metabolism - Pathology | en_US |
dc.subject.mesh | Corneal Neovascularization - Etiology - Metabolism - Pathology | en_US |
dc.subject.mesh | Disease Models, Animal | en_US |
dc.subject.mesh | Fibroblast Growth Factors - Metabolism | en_US |
dc.subject.mesh | Gene Expression Regulation - Physiology | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Lymphangiogenesis - Genetics - Physiology | en_US |
dc.subject.mesh | Matrix Metalloproteinases - Genetics - Metabolism | en_US |
dc.subject.mesh | Vascular Endothelial Growth Factor A - Metabolism | en_US |
dc.subject.mesh | Wound Healing - Physiology | en_US |
dc.title | Novel aspects of corneal angiogenic and lymphangiogenic privilege | en_US |
dc.type | Article | en_US |
dc.identifier.email | Zhou, Z:zhongjun@hkucc.hku.hk | en_US |
dc.identifier.authority | Zhou, Z=rp00503 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1016/j.preteyeres.2010.01.002 | en_US |
dc.identifier.pmid | 20100589 | - |
dc.identifier.scopus | eid_2-s2.0-77951206611 | en_US |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-77951206611&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 29 | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.spage | 208 | en_US |
dc.identifier.epage | 248 | en_US |
dc.identifier.isi | WOS:000277826800003 | - |
dc.publisher.place | United Kingdom | en_US |
dc.identifier.scopusauthorid | Ellenberg, D=14059790000 | en_US |
dc.identifier.scopusauthorid | Azar, DT=26643368400 | en_US |
dc.identifier.scopusauthorid | Hallak, JA=15122112400 | en_US |
dc.identifier.scopusauthorid | Tobaigy, F=15123368000 | en_US |
dc.identifier.scopusauthorid | Han, KY=7402960197 | en_US |
dc.identifier.scopusauthorid | Jain, S=35184745300 | en_US |
dc.identifier.scopusauthorid | Zhou, Z=8631856300 | en_US |
dc.identifier.scopusauthorid | Chang, JH=22333289500 | en_US |
dc.identifier.citeulike | 6599254 | - |
dc.identifier.issnl | 1350-9462 | - |